Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XACT: Rivaroxaban vs Enoxaparin in Hospitalized COVID-19 Patients
NCT04640181Phase 2Completed
- Sponsor
- St. David's HealthCare
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban in coronavirus disease 2019 (COVID-19), sponsored by St. David's HealthCare. Started Dec 2020; status: completed.
02
Drugs
rivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04640181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640181.